SCHEMBL12008793

SCHEMBL12008793

Cc1ccc(/C=C2\SC(=S)N(CCCC(=O)Nc3cccc(C(=O)O)c3)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 13/20 1.00
▸ GPR35 Q9HC97 8/20 1.00
▸ PTPN12 Q05209 7/20 1.00
▸ PTPN22 Q9Y2R2 6/20 1.00
▸ PTPN7 P35236 5/20 1.00
▸ GPR55 Q9Y2T6 3/20 1.00
▸ MEN1 O00255 11/20 0.86
▸ PSMD14 O00487 1/20 0.79
▸ POLB P06746 4/20 0.75
▸ NPC1 O15118 3/20 0.75
▸ TDP1 Q9NUW8 3/20 0.75
▸ CTDSP1 Q9GZU7 3/20 0.75
▸ BLM P54132 2/20 0.75
▸ MAPT P10636 6/20 0.74
▸ RAB9A P51151 3/20 0.74
▸ KDM4E B2RXH2 2/20 0.74
▸ GAA P10253 1/20 0.74
▸ APEX1 P27695 1/20 0.73
▸ RECQL P46063 1/20 0.73
▸ MAPK1 P28482 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12008778 0.95 KMT2A (0.90) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008764 0.93 KMT2A (1.00) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008774 0.91 KMT2A (0.90) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008755 0.91 KMT2A (0.86) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008757 0.91 KMT2A (0.90) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008734 0.91 KMT2A (0.83) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008794 0.89 KMT2A (0.84) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL13695120 0.88 KMT2A (0.87) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008614 0.88 PTPN12 (1.00) KMT2AGPR35PTPN12PTPN22PTPN7
SCHEMBL12008579 0.87 PTPN12 (0.86) KMT2AGPR35PTPN12PTPN22PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4503/4885GPR35 302/4885PTPN12 226/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885GPR35 299/4885PTPN12 457/4885
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885GPR35 299/4885PTPN12 457/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 KMT2A 4591/4885GPR35 299/4885PTPN12 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback